Elizabeth Lowe
A5034781155- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- BRCA gene mutations in cancer
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Literature, Culture, and Criticism
- Colorectal Cancer Treatments and Studies
- Estrogen and related hormone effects
- Cultural, Media, and Literary Studies
- Breast Cancer Treatment Studies
- American Constitutional Law and Politics
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Cuban History and Society
- Acute Lymphoblastic Leukemia research
- Historical Studies in Latin America
- Cancer Treatment and Pharmacology
- Colonialism, slavery, and trade
- Opioid Use Disorder Treatment
- Borges, Kipling, and Jewish Identity
- Childhood Cancer Survivors' Quality of Life
- Cancer Genomics and Diagnostics
- Neutropenia and Cancer Infections
- 3D Printing in Biomedical Research
AstraZeneca (United States)
2014-2024
Institute of Cancer Research
2023
Medical College of Wisconsin
2023
Dana-Farber Cancer Institute
2023
Cancer Research UK
2023
AstraZeneca (Italy)
2023
Clinica Universidad de Navarra
2023
AstraZeneca (Brazil)
2011-2023
AstraZeneca (United Kingdom)
2008-2021
AstraZeneca (Japan)
2018-2020
Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate–ribose) polymerase inhibitor olaparib in relapsed disease has been well established, but as maintenance therapy is uncertain.
Purpose The third-generation nonsteroidal aromatase inhibitors (AIs) are increasingly used as adjuvant and first-line advanced therapy for postmenopausal, hormone receptor–positive (HR+) breast cancer. Because many patients subsequently experience progression or relapse, it is important to identify agents with efficacy after AI failure. Materials Methods Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) a randomized, double-blind, placebo controlled, multicenter phase III trial...
Purpose Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or BRCA2-deficient cells, has shown promising clinical efficacy nonrandomized phase II trials patients with ovarian cancer BRCA1 BRCA2 deficiency. We assessed the comparative and safety of olaparib pegylated liposomal doxorubicin (PLD) this patient population. Patients Methods In multicenter, open-label, randomized, study, recurred within 12 months prior platinum...
In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients newly diagnosed advanced ovarian cancer and BRCA1 and/or BRCA2 (BRCA) mutation. We report overall (OS) after 7-year follow-up, clinically relevant time point longest follow-up for any first-line setting.This double-blind phase III trial randomly assigned BRCA mutation clinical response to...
PURPOSE A phase II study (ClinicalTrials.gov identifier: NCT00628251 ) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resistant or partially platinum-sensitive relapsed ovarian cancer. We conducted a III trial (SOLO3) tablets nonplatinum chemotherapy cancer who had received at least 2 prior lines platinum-based chemotherapy. PATIENTS AND METHODS In this randomized, open-label trial, were randomly assigned 2:1 to 300...
In Study 19, maintenance monotherapy with olaparib significantly prolonged progression-free survival vs placebo in patients platinum-sensitive, recurrent high-grade serous ovarian cancer. 19 was a randomised, placebo-controlled, Phase II trial enrolling 265 who had received at least two platinum-based chemotherapy regimens and were complete or partial response to their most recent regimen. Patients randomised (capsules; 400 mg bid) placebo. We present long-term safety final mature overall...
Abstract Introduction This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel patients metastatic triple-negative breast cancer (mTNBC). Methods Eligible who had received ≤1 prior cytotoxic regimen for mTNBC were treated olaparib 200 mg bid continuously plus weekly 90 mg/m 2 three weeks per four-week cycle. Dose modifications large proportion due to neutropenia resulted...
In SOLO1, maintenance olaparib (300 mg twice daily) significantly improved progression-free survival (PFS) for patients with newly diagnosed
Abstract Purpose: The efficacy, safety, and tolerability of cediranib plus olaparib (cedi/ola) were investigated in patients with nongermline–BRCA-mutated (non-gBRCAm) platinum-resistant recurrent ovarian cancer. Patients Methods: PARP inhibitor–naïve women aged ≥18 years non-gBRCAm cancer, ECOG performance status 0–2, ≥3 prior lines therapy received 30 mg once daily 200 twice this single-arm, multicenter, phase IIb trial. primary endpoint was objective response rate (ORR) by independent...
(Abstracted from J Clin Oncol 2022; doi: 10.1200/JCO.22.01549) Because of nonspecific symptoms at disease presentation and inadequate screening methods, ovarian cancer is often advanced the time diagnosis results in a 10-year survival 17% patients with epithelial cancer. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib new standard care newly diagnosed BRCA1 and/or BRCA2 (BRCA) mutation.
(Abstracted from N Engl J Med 2018;379:2495–2505) Standard-of-care therapy for patients newly diagnosed with advanced ovarian cancer consists of frontline cytoreductive surgery and adjuvant platinum chemotherapy. Approximately 70% these have a relapse within 3 years.
In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a substantial progression-free survival benefit in patients with newly diagnosed, advanced ovarian cancer and BRCA mutation who were response after platinum-based chemotherapy. We analyzed timing, duration grade of most common hematologic non-hematologic adverse events SOLO1.Eligible randomized to tablets 300 mg twice daily (N = 260) or placebo 131), 2-year treatment cap patients. Safety outcomes detail received at...
(Abstracted from Lancet Oncol 2021;22:620–631) The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is approved as maintenance therapy in newly diagnosed ovarian cancer or patients with platinum-sensitive, relapsed regardless of BRCA1/2 mutation status. primary analysis the SOLO2/ENGOT-Ov21 phase 3 trial found a significant improvement median progression-free survival associated treatment compared placebo and mutation.